Document is current
Any future updates will be listed below
-
Authors
Slart, Riemer H. J. A.
Punda, Marija
Ali, Dalal S.
Bazzocchi, Alberto
Bock, Oliver
Camacho, Pauline
Carey, John J.
Colquhoun, Anita
Compston, Juliet
Engelke, Klaus
Erba, Paola A.
Harvey, Nicholas C.
Krueger, Diane
Lems, Willem F.
Lewiecki, E. Michael
Morgan, Sarah
Moseley, Kendall F.
O’Brien, Christopher
Probyn, Linda
Rhee, Yumie
Richmond, Bradford
Schousboe, John T.
Shuhart, Christopher
Ward, Kate A.
Van den Wyngaert, Tim
Zhang-Yin, Jules
Khan, Aliya A.
,
- License Information
-
More Information
Article History
Received: 2 July 2024
Accepted: 28 August 2024
First Online: 24 September 2024
Declarations
:
: RHJAS: Unrestricted research grants of Pfizer and Siemens Healthineers; MP: None ; DSA: None; AB: Speaker/Consulting fee, GE Healthcare; OB: None; PC: None ; JJC: None ; AC: None; JC: None; KE: None; PAE: None; NCH: None; DK: None; WFL: Speakers fee/advisory Boards: UCB, Amgen, Galapagos, Pfizer; EML: Amgen: investigator, consultant, speaker; Radius: investigator, consultant, speaker; Kyowa Kirin: consultant, speaker; Ultragenyx: investigator; Angitia: consultant; Ascendis: consultant; UpTo Date: royalties; SM: None; KFM: None; CO: None; LP: None; YR: Speaker: Amgen, Dawoong; Investigator: Amgen, Kyowa Kirin, Dongguk, Dong-A, Daewoong; BR: None; JTS: None; CS: None; KAW: None; TVW:none; JTZ: None; AAK: Speaker, advisory board (Alexion, Amgen); Speaker, advisory board, research funding (Ascendis); Advisory board, research funding (Takeda); Research funding (Amolyt, Calcilytix).
: This article does not contain any studies with human participants or animals performed by any of the authors.
: RHJAS is Associate Editor of the EJNMMI.
